Answers are grounded in this paper and cite their sources.
values from 0.5 nM (boscalid) to 100 μM (kasugamycin). The diversity of products and their molecular targets underline the multiplicity of approaches currently investigated to tackle leaf spot disease. On this basis, novel products and combinations can be proposed and the battle is going again.
No takes yet. Share an insight, caveat, or question.
Christian Bailly (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: